Skip to main content
Print Save

Gammagard Liquid FDA Approval History

FDA Approved: Yes (First approved May 2, 2005)
Brand name: Gammagard Liquid
Generic name: immune globulin infusion (human)
Dosage form: Solution
Company: Baxter Healthcare Corporation
Treatment for: Primary Immunodeficiency Syndrome

Gammagard (immune globulin infusion (human)) is an immune globulin infusion (human) indicated as replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients two years of age or older.

Development Timeline for Gammagard Liquid

DateArticle
Jun 26, 2012Approval  Baxter Announces FDA Approval for Gammagard Liquid as a Treatment for Multifocal Motor Neuropathy
Jul 25, 2011Approval  Baxter Announces FDA Approval of Subcutaneous Route of Administration for Gammagard Liquid for Patients with Primary Immunodeficiency
May  2, 2005Approval  Gammagard Liquid Baxter Healthcare Corporation - Treatment for Primary Immunodeficiency Disorders

See Also

Gammagard Liquid (immune globulin infusion (human)) Consumer Information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer